Clinical enigma: Case-based systematic review of flumazenil in the management of paradoxical reactions to midazolam - A quarter-century perspective.

Background and Aims: The mechanism of paradoxical reaction is still a big question for the medical world, but several theoretical approaches have arisen. Midazolam, a high-potency benzodiazepine, carries a higher risk of paradoxical reaction. Paradoxical reactions associated with midazolam are often misunderstood and mismanaged, with clinicians frequently attributing them to factors like inadequate dosing or low sedation levels. This leads to the common practice of escalating midazolam dosage or exploring alternative sedatives, despite flumazenil offering a safer solution theoretically. Flumazenil emerges as a viable antidote as it swiftly and effectively reverses paradoxical reactions, proving to be a safer alternative to dose escalation strategies. Material and Methods: In this systematic review, we conducted a search regarding the use of flumazenil in midazolam-induced paradoxical reactions over a quarter-century period (1998-2023) in three databases. We include 10 case reports presenting a total of 14 cases, which adhered to the specified inclusion criteria. Result: We selected 10 case reports published from 1998 to 2023 with a total of 14 cases. Study characteristics, patient demographics, midazolam dose and administration route, incident of paradoxical effect, flumazenil dose and administration route, and outcome of flumazenil administration. Conclusions: All the cases showed the prosperous effectiveness of flumazenil in reducing paradoxical reaction symptoms with no adverse effect on hemodynamics. Ongoing research and study in this field are essential to refine protocols and enhance patient outcomes.